Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

With Perjeta, The Cost Of HER2 Breast Cancer Therapy Goes Up

Jun 18 2012

• By Jessica Merrill

Related Content

Pfizer’s <i>Xalkori</i> Joins The Six-Figure Oncology Drug Club

Sep 05 2011

Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster

May 07 2012

Beyond Herceptin, Roche Readies Breast Cancer Successors, Braces For Biosimilars

Jun 11 2012

Buoyed By T-DM1 EMILIA Data, Roche Leaps To Early Breast Cancer Trial

Jun 04 2012

Genentech’s <em>Perjeta</em> Clears FDA Despite Unresolved Manufacturing Issues

Jun 18 2012

Related Companies

Roche Holding AG

Genentech, Inc.

Dendreon Corporation

Bristol Myers Squibb Company

Seagen Inc.

Agilent Technologies, Inc.

ImmunoGen, Inc.

Additional Topics

Reimbursement Pricing Strategies Launches BioPharmaceutical

More from Market Access

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window